Hansa Biopharma Year-end report January-December 2023
· Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain · Encouraging results from first-in-human trial of HNSA-5487 · Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SRP-9001 in DMDLund, Sweden, February 2, 2024, Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and year-end report for January to December 2023. Highlights for the fourth quarter of 2023 · Strong commercial